Neoadjuvant therapy for non-small cell lung cancer

Area of Science:

• Oncology
• Thoracic Surgery
• Medical Oncology

Background:

• Neoadjuvant therapy for locally advanced non-small cell lung cancer (NSCLC) is feasible and tolerable.
• Randomized trials show improved survival with preoperative chemotherapy plus surgery for stage III NSCLC.
• Neoadjuvant chemotherapy combined with thoracic radiotherapy increases pathologic response but also toxicity.

Purpose of the Study:

• To evaluate neoadjuvant therapy as a paradigm for clinical research in NSCLC.
• To assess the role of neoadjuvant therapy as an in vivo test of chemosensitivity.
• To explore novel chemotherapeutic agents and strategies in the neoadjuvant setting for NSCLC.

Main Methods:

• Review of clinical trials evaluating neoadjuvant or preoperative therapy for locally advanced NSCLC.
• Analysis of randomized trials comparing preoperative chemotherapy and surgery versus surgery alone.
• Investigation of combined neoadjuvant chemotherapy and thoracic radiotherapy.

Main Results:

• Preoperative chemotherapy followed by surgery improved survival in stage III NSCLC patients.
• Neoadjuvant chemotherapy plus thoracic radiotherapy yielded higher pathologic response rates but increased toxicity.
• Docetaxel, a potent radiosensitizer, shows feasibility and encouraging results in neoadjuvant strategies for NSCLC.

Conclusions:

• Neoadjuvant therapy is an important research paradigm for NSCLC, offering a window for testing new agents.
• The optimal neoadjuvant approach for NSCLC may be substage dependent.
• Docetaxel integration into neoadjuvant treatment strategies for NSCLC is feasible and shows promising results.